Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on ...

Revolutionary drug Lepodisiran dramatically lowers Lp(a) cholesterol, a major heart attack risk factor. Learn about this ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.